Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dostarlimab Fills Unmet Need for Patients with dMMR Advanced Endometrial Cancer

March 20th 2023

Lucy Gilbert, MD, MSc, discusses the favorable safety profile of dostarlimab as well as how it compares with the current standard of care in mismatch repair deficient advanced endometrial cancer.

Coleman Illuminates Opportunities in Gynecologic Malignancies

March 17th 2023

Robert L. Coleman, MD, FACOG, FACS, the 2020 Giants of Cancer Care® award winner in gynecologic malignancies, notes that despite the great progress in the past decade, more work is needed to personalize and refine approaches to care.

Minimally Invasive Surgery, PARP Inhibitors, ADCs Propel Treatment Advances Across Gynecologic Oncology

March 9th 2023

Jubilee Brown, MD, discusses future considerations for using minimally invasive surgery and PARP inhibitors in ovarian cancer, how immunotherapies have fulfilled an unmet need in cervical cancer, and the importance of leveraging molecular profiling to determine personalized therapeutic strategies in endometrial cancer.

Lenvatinib Plus Pembrolizumab Generates Durable Responses in Advanced Endometrial Carcinoma

February 26th 2023

Lenvatinib in combination with pembrolizumab led to deep and durable tumor responses in patients with previously treated advanced endometrial carcinoma.

Dr. Barber on the Role of Molecular Profiling for Treatment Considerations in Endometrial Cancer

February 23rd 2023

Emma L. Barber, MD, discusses the role of molecular profiling for treatment considerations in patients with endometrial cancer.

State of Science Summit- Ovarian Cancer: Chaired by Jubilee Brown, MD & Wendell Naumann, MD

February 16th 2023

State of Science Summit- Ovarian Cancer: Chaired by Jubilee Brown, MD & Wendell Naumann, MD

Long-term Data for Niraparib Support Continued Use of PARP Inhibitors in HRD+ Ovarian Cancer

February 14th 2023

Dario R. Roque, MD, discusses incorporating PARP inhibitors into practice for patients with homologous recombination deficient ovarian cancer, the role of PARP inhibitors for patients with homologous recombination–proficient ovarian cancer and the expanding investigation of mirvetuximab soravtansine in ovarian cancer.

FDA Grants Regular Approval to Dostarlimab for dMMR Endometrial Cancer

February 9th 2023

The FDA has granted a regular approval to dostarlimab-gxly (Jemperli) for adult patients with mismatch repair–deficient, recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.

Biomarkers Clarify Treatment Decisions and Sequencing in Endometrial Cancer

February 9th 2023

Emma L. Barber, MD, emphasized the importance of the ongoing phase 3 PORTEC-4a trial, which is investigating the role of molecular risk profiles in determining whether patients with endometrial cancer should receive no adjuvant therapy, vaginal brachytherapy, or external beam radiotherapy.

ONA-XR/Anastrozole Combo Delivers Promising Early Results in HR+ Metastatic Endometrial Cancer

February 8th 2023

Oral progesterone receptor antagonist onapristone extended release in combination with anastrozole induced a confirmed partial response in 2 patients with hormone receptor–positive metastatic endometrial cancer.

Dr. Herzog on the FDA Approval of Mirvetuximab Soravtansine in FRα–positive Gynecologic Cancers

February 6th 2023

Thomas Herzog, MD, discusses how the recent FDA approval of the novel antibody-drug conjugate mirvetuximab soravtansine-gynx ameliorates unmet need in platinum-resistant, folate receptor alpha–positive gynecological cancers.

First-line Pembrolizumab Plus Chemo Meets PFS End Point in Advanced or Recurrent Endometrial Carcinoma

February 3rd 2023

The combination of pembrolizumab plus carboplatin and paclitaxel demonstrated a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in the first-line treatment of patients with stage III/IV or recurrent endometrial cancer.

Avutometinib Plus Defactinib Generates Responses in Recurrent Low-Grade Serous Ovarian Cancer

January 25th 2023

The combination of avutometinib and defactinib elicited responses in patients with recurrent low-grade serous ovarian cancer, according to data from a planned interim analysis of the registration-directed phase 2 RAMP-201 trial.

FDA Grants Fast Track Designation to DB-1303 for HER2-Overexpressed Advanced/Recurrent Endometrial Cancer

January 23rd 2023

The FDA has granted a fast track designation to DB-1303 for the treatment of patients with advanced, recurrent or metastatic endometrial cancer with HER2 overexpression who have progressed on or after standard systemic therapy.

State of Science Summit- Ovarian Cancer: Chaired by Dario Roque, MD

January 17th 2023

State of Science Summit- Ovarian Cancer: Chaired by Dario Roque, MD

Genetic Analysis Helps Maximize Clinical Benefit with PARP Inhibitors in BRCA+ Ovarian Cancer

January 17th 2023

Saketh Guntupalli, MD, highlights data supporting PARP inhibitors as the standard-of-care frontline therapy, strategies for the management of PARP-related toxicities, and the importance of testing for HRD and BRCA status in patients with ovarian cancer.

Targeting FRα Enters a New Era in Ovarian Cancer and Beyond

January 16th 2023

Efforts to target the folate metabolism network have entered a new stage, with the approval of a novel therapy directed at folate receptor–α and the potential for additional agents aimed at that target in solid tumors.

Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

January 13th 2023

Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.

Greatest Unmet Needs for Patients with Endometrial Cancer

January 13th 2023

The panel shares the most critical unmet needs for patients with endometrial cancer.

COM701 Plus BMS-986207/Nivolumab Shows Early Activity in Platinum-resistant Ovarian Cancer

January 12th 2023

A triplet regimen comprised of COM701, BMS-986207, and nivolumab was found to have encouraging antitumor activity and favorable tolerability in patients with heavily pretreated, platinum-resistant ovarian cancer.